QNRX

Materials

Quoin Pharmaceuticals Ltd

$6.43+0.12 (+1.90%)PRE

Live · NASDAQ · May 9, Close

AI Insight

What's Moving QNRX Today?

No stock-specific AI insight has been generated for QNRX yet. Check back soon — insights are generated from recent news analysis.

Fundamentals

Market Cap$12M

P/E Ratio—

EPS—

Dividend Yield—

Dividend / Share—

ROE—

Profit Margin—

Debt / Equity—

Trading

Volume8K

Avg Volume (10D)—

Shares Outstanding1.8M

QNRX News

20 articles

Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial ResultsYahoo Finance·May 7, 2026
Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026Yahoo Finance·Apr 30, 2026
CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development ProgramsYahoo Finance·Apr 28, 2026
Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development ProgramsYahoo Finance·Apr 28, 2026
QNRX: Preparing to Commercialize Lead Asset Through Global Sales InfrastructureYahoo Finance·Apr 15, 2026
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial ResultsYahoo Finance·Mar 26, 2026
Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton SyndromeYahoo Finance·Mar 25, 2026
Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026Yahoo Finance·Mar 19, 2026
Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton SyndromeYahoo Finance·Mar 11, 2026
NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton SyndromeYahoo Finance·Feb 26, 2026
QNRX: Advancing Lead Asset QRX003, With Extensive Distribution Network in Place to Support Commercialization ProspectsYahoo Finance·Feb 25, 2026
Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton SyndromeYahoo Finance·Jan 27, 2026
Quoin Pharmaceuticals Insider Ups Holding By 1,515,200% During YearYahoo Finance·Jan 23, 2026
Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton SyndromeYahoo Finance·Jan 20, 2026
QNRX: Several Recent Milestones - Cash Runway Extended into ‘27, Orphan Drug Designation Received, Positive Interim DataYahoo Finance·Nov 20, 2025
Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery TechnologiesYahoo Finance·Nov 11, 2025
Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial ResultsYahoo Finance·Nov 6, 2025
Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025Yahoo Finance·Oct 30, 2025
Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month ‘Whole Body’ Data Update from Ongoing StudyYahoo Finance·Oct 28, 2025
Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton SyndromeYahoo Finance·Oct 21, 2025

All 20 articles loaded

Price Data

Open$6.38

Previous Close$6.31

Day High$6.40

Day Low$6.31

52 Week High—

52 Week Low—

Fundamentals

Market Cap$12M

P/E Ratio—

EPS—

Dividend Yield—

Dividend / Share—

ROE—

Profit Margin—

Debt / Equity—

Trading

Volume8K

Avg Volume (10D)—

Shares Outstanding1.8M

About Quoin Pharmaceuticals Ltd

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

quoinpharma.com

6 employees

Listed October 28, 2021

MaterialsPHARMACEUTICAL PREPARATIONS

Company Details

Security TypeStock

ExchangeNASDAQ

Currency—

Round Lot—

SICPHARMACEUTICAL PREPARATIONS

CIK—

Composite FIGI—

Share Class FIGI—